Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Concord BiotechBOM:543960 +3.61%90 Days Inventory is 548.53 as of Jun. 2026, which is 53% above its 10-year median of 357.70. GuruFocus rates BOM:543960 with a GF Score™ of 90/100 and a GF Value™ of ₹1,635.84 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 638 Biotechnology companies, Concord Biotech ranks worse than 78.06% on this metric.
The historical rank and industry rank for Concord Biotech's Days Inventory or its related term are showing as below:
BOM:543960'
s Days Inventory Range Over the Past 10 Years
Min: 257.13 Med: 357.7 Max: 402.11
Current: 402.11
During the past 7 years, Concord Biotech's highest Days Inventory was 402.11. The lowest was 257.13. And the median was 357.70.
BOM:543960's Days Inventory is ranked worse than 78.06% of 638
companies
in the Biotechnology industry
Industry Median: 179.22
vs BOM:543960: 402.11
Concord Biotech's Days Inventory
increased
from Jun. 2025 (484.86) to Jun. 2026 (548.53).
It might indicate that Concord Biotech's sales slowed down.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Concord Biotech's Inventory Turnover for the
three
months ended in Jun. 2026 was 0.17.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Concord Biotech's Inventory-to-Revenue for the
three
months ended in Jun. 2026 was 1.27.
Concord Biotech (BOM:543960) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Concord Biotech's Inventory Turnover for the
three
months ended in Jun. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Concord Biotech's Inventory to Revenue for the
three
months ended in Jun. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Concord Biotech Days Inventory Related Terms
Concord Biotech Days Inventory Historical Data
* Premium members only.
The historical data trend for Concord Biotech's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:543960 vs VRTX, REGN, RVMD: Days Inventory Comparison
For the Biotechnology subindustry, Concord Biotech's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Concord Biotech Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Concord Biotech's Days Inventory distribution charts can be found below:
* The bar in red indicates where Concord Biotech's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Concord Biotech (BOM:543960) has a Days Inventory of 548.53 as of Jun. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Concord Biotech and its competitors. This is 53% above median its historical median of 357.70. Over the past decade, Concord Biotech's Days Inventory has ranged from 257.13 to 402.11. According to the industry distribution chart, Concord Biotech ranks #498 out of 638 companies in the Biotechnology industry, placing it in the top 78.1%.
Is Concord Biotech's Days Inventory too high?
Concord Biotech's current Days Inventory of 548.53 is 53% above median its 10-year median of 357.70. Over the past 10 years, this metric has ranged from a low of 257.13 to a high of 402.11. The Biotechnology industry median Days Inventory is 179.22. Concord Biotech's value of 548.53 is 206.1% above this industry median. Based on the distribution chart, Concord Biotech ranks #498 out of 638 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Concord Biotech has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Concord Biotech's Days Inventory compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Concord Biotech ranks #498 out of 638 companies for Days Inventory. This places Concord Biotech in the lower half of its industry. The industry median Days Inventory is 179.22. Concord Biotech's value of 548.53 is 206.1% above this benchmark. Historically, Concord Biotech's own Days Inventory has ranged from 257.13 to 402.11 over the past decade. While the company's 10-year median is 357.70 vs. the industry median of 179.22, Concord Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 179.22, based on 638 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Concord Biotech's current Days Inventory of 548.53 is 206.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Concord Biotech and its competitors. For the Biotechnology industry, the median Days Inventory is 179.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Concord Biotech's current Days Inventory is 548.53, which is 53% above median its own 10-year median of 357.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Concord Biotech stock overvalued right now?
Based on GuruFocus' analysis, Concord Biotech (BOM:543960) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹1,635.84, compared to a current price of ₹1,430.35 — trading 12.6% below its estimated fair value. The current Days Inventory is 548.53, which is 53% above median its 10-year median of 357.70 and 206.1% above the Biotechnology industry median of 179.22. Concord Biotech's overall GF Score™ is 90/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Concord Biotech (BOM:543960), the current Days Inventory is 548.53 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Concord Biotech (BOM:543960) Overvalued in 2026?
Based on GuruFocus' analysis, Concord Biotech stock appears to be undervalued.
The current stock price of ₹1,430.35 is trading 12.6% below its estimated GF Value™ of ₹1,635.84.
GuruFocus considers Concord Biotech to be Modestly Undervalued.
Key valuation signals for BOM:543960:
Days Inventory: 548.53 (53% above median its 10-year median of 357.70)
GF Value™: ₹1,635.84 vs. price of ₹1,430.35 (12.6% below fair value)
Industry Position: 206.1% above the Biotechnology median (#498 of 638)
No single metric tells the full story. See the BOM:543960 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Concord Biotech Ltd is a research and development-driven biopharma company that manufactures Active Pharmaceutical Ingredients (API) through fermentation and semi-synthetic process and finished formulations. It is mainly engaged in the business of manufacturing and trading in pharmaceutical products. Geographically Company operates in two segments within India and outside India, having majority revenue from India.
90GF Score
Get the complete analysis for BOM:543960
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543960 has been successfully added to your 
